<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003926</url>
  </required_header>
  <id_info>
    <org_study_id>1997LS053</org_study_id>
    <secondary_id>UMN-MT-9713</secondary_id>
    <secondary_id>UMN-9712M00074</secondary_id>
    <nct_id>NCT00003926</nct_id>
  </id_info>
  <brief_title>Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors</brief_title>
  <official_title>A Phase I Study of the Chemoprotectant Amifostine With Autologous Stem Cell Transplantation for High Risk or Relapsed Pediatric Solid Tumors and Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation
      may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.
      Chemoprotective drugs such as amifostine may protect normal cells from the side effects of
      high-dose chemotherapy.

      PURPOSE: Phase I trial to study the effectiveness of amifostine in protecting from the side
      effects of peripheral stem cell transplantation in treating patients who have high-risk or
      relapsed solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the dose-limiting toxicity of amifostine chemoprotection with peripheral blood
           stem cell transplantation plus chemotherapy in patients with high-risk or relapsed solid
           tumors or brain tumors.

        -  Determine response or time to disease progression in patients treated with this regimen.

      OUTLINE: This is a dose-escalation study of amifostine. Patients are stratified according to
      age (1 to 18 vs 19 to 45 years).

      All patients receive filgrastim (G-CSF) IV for 1 week. On day 6 of G-CSF administration,
      patients undergo peripheral blood stem cell (PBSC) harvest followed by chemotherapy.

      Patients receive oral busulfan every 6 hours on days -8 to -6 followed by melphalan IV over
      30 minutes on days -5 and -4 and thiotepa IV over 2 hours on days -3 and -2. Patients receive
      amifostine IV over 5 minutes beginning 30 minutes prior to melphalan and thiotepa
      administration on days -5 to -1. PBSC are reinfused on day 0.

      Cohorts of 3-6 patients receive escalating doses of amifostine until the maximum tolerated
      dose is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6
      patients experience dose-limiting toxicity.

      Patients are followed on day 50; at 3, 6, and 9 months; and at 1, 2, and 3 years post PBSC
      transplantation.

      PROJECTED ACCRUAL: A maximum of 60 patients (30 per stratum) will be accrued for this study
      within 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Withdrawn due to slow accrual
  </why_stopped>
  <start_date>November 1998</start_date>
  <completion_date type="Actual">August 2003</completion_date>
  <primary_completion_date type="Actual">August 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Childhood Germ Cell Tumor</condition>
  <condition>Chordoma</condition>
  <condition>Kidney Cancer</condition>
  <condition>Liver Cancer</condition>
  <condition>Neuroblastoma</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Retinoblastoma</condition>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Solid/brain tumor patients (1-18 years)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with solid tumor or brain tumor in the 1-18 years old stratum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solid/brain tumor patients (19-45 years)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with solid tumor or brain tumor in the 19-45 years old stratum.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amifostine trihydrate</intervention_name>
    <description>Patients receive amifostine intravenous (IV) over 5 minutes beginning 30 minutes prior to melphalan and thiotepa administration on days -5 to -1.
Cohorts of 3-6 patients receive escalating doses of amifostine until the maximum tolerated dose is determined.</description>
    <arm_group_label>Solid/brain tumor patients (1-18 years)</arm_group_label>
    <arm_group_label>Solid/brain tumor patients (19-45 years)</arm_group_label>
    <other_name>Ethyol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>Patients receive oral busulfan every 6 hours on days -8 to -6.</description>
    <arm_group_label>Solid/brain tumor patients (1-18 years)</arm_group_label>
    <arm_group_label>Solid/brain tumor patients (19-45 years)</arm_group_label>
    <other_name>Busulfex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>All patients receive filgrastim (G-CSF) IV for 1 week.</description>
    <arm_group_label>Solid/brain tumor patients (1-18 years)</arm_group_label>
    <arm_group_label>Solid/brain tumor patients (19-45 years)</arm_group_label>
    <other_name>granulocyte colony-stimulating factor</other_name>
    <other_name>G-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>melphalan intravenous (IV) over 30 minutes on days -5 and -4</description>
    <arm_group_label>Solid/brain tumor patients (1-18 years)</arm_group_label>
    <arm_group_label>Solid/brain tumor patients (19-45 years)</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiotepa</intervention_name>
    <description>thiotepa intravenous (IV) over 2 hours on days -3 and -2.</description>
    <arm_group_label>Solid/brain tumor patients (1-18 years)</arm_group_label>
    <arm_group_label>Solid/brain tumor patients (19-45 years)</arm_group_label>
    <other_name>Thioplex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation (PBSC)</intervention_name>
    <description>PBSC are reinfused on day 0</description>
    <arm_group_label>Solid/brain tumor patients (1-18 years)</arm_group_label>
    <arm_group_label>Solid/brain tumor patients (19-45 years)</arm_group_label>
    <other_name>bone marrow transplant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed high-risk or relapsed solid tumors or brain tumors,
             including:

               -  Metastatic or relapsed Ewing's sarcoma

               -  Metastatic or relapsed rhabdomyosarcoma

               -  Refractory Wilms' tumor

               -  Diffuse anaplastic Wilms' tumor

               -  Stage III or IV neuroblastoma

               -  Recurrent retinoblastoma

               -  Metastatic or relapsed germ cell tumors

               -  Metastatic or relapsed other soft tissue sarcomas

               -  Small cell ovarian sarcoma

               -  Metastatic or relapsed primitive neuroectodermal tumors of the bone

               -  Recurrent brain tumors

               -  Desmoplastic small round cell tumors

               -  Recurrent or metastatic chordomas

               -  Metastatic or relapsed hepatoblastoma

          -  Patients receive peripheral blood stem cell transplantation only if in complete
             remission or in very good partial remission with no disease progression

          -  Must have radiologic, nuclear image, or histologic verification of relapse

          -  Age 1 to 45

          -  Performance status:Karnofsky 70-100%

          -  Absolute neutrophil count greater than 1,000/mm^3

          -  Platelet count greater than 100,000/mm^3

          -  Hemoglobin count at least 10 g/dL

          -  Bilirubin less than 2 times upper limit of normal (ULN)

          -  SGOT or SGPT less than 2.5 times ULN

          -  Creatinine less than 2 times ULN

          -  Creatinine clearance greater than 70 mL/min

          -  Cardiac shortening fraction greater than 30%

          -  Cardiac ejection fraction greater than 45%

          -  At least 1 week since prior hematopoietic growth factor and recovered

          -  At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered

          -  Recovered from any prior therapy

        Exclusion Criteria:

          -  Osteogenic sarcoma

          -  Less than 4 months

          -  Uncontrolled bleeding

          -  Congestive heart failure

          -  Uncontrolled hypertension

          -  Asthma

          -  Pregnant or nursing

          -  Uncontrolled metabolic disease

          -  Active severe infection

          -  Allergy to aminothiol compounds

          -  Prior bone marrow transplantation

          -  Other concurrent investigational agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John P. Perentesis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>May 1, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2003</study_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2017</last_update_posted>
  <responsible_party>
    <name_title>John Perentesis, MD</name_title>
    <organization>Masonic Cancer Center, University of Minnesota</organization>
  </responsible_party>
  <keyword>soft tissue sarcoma</keyword>
  <keyword>regional neuroblastoma</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>recurrent Wilms tumor</keyword>
  <keyword>recurrent retinoblastoma</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult rhabdomyosarcoma</keyword>
  <keyword>ovarian germ cell tumor</keyword>
  <keyword>chordoma</keyword>
  <keyword>ovarian sarcoma</keyword>
  <keyword>unresectable neuroblastoma</keyword>
  <keyword>desmoplastic small round cell tumor</keyword>
  <keyword>rhabdomyosarcoma</keyword>
  <keyword>Ewing sarcoma</keyword>
  <keyword>neuroectodermal tumor</keyword>
  <keyword>teratoma</keyword>
  <keyword>malignant testicular germ cell tumor</keyword>
  <keyword>malignant ovarian germ cell tumor</keyword>
  <keyword>extragonadal germ cell tumor</keyword>
  <keyword>malignant germ cell tumor</keyword>
  <keyword>hepatoblastoma</keyword>
  <keyword>liver cancer</keyword>
  <keyword>medulloblastoma</keyword>
  <keyword>cerebellar astrocytoma</keyword>
  <keyword>brain stem glioma</keyword>
  <keyword>glioma</keyword>
  <keyword>cerebral astrocytoma</keyword>
  <keyword>ependymoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Retinoblastoma</mesh_term>
    <mesh_term>Chordoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Amifostine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

